Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T18:05:32.677Z.
Calculation as of: 2026-10-06T18:05:32.677Z.
Quote observation: 2026-10-06T18:00:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2f5c47113f9c506e2e082fd2a1fe30760bd520268ada69101bb9e18573fa4dd9
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$862.57M
EV/FCF Ratio
10.60x
TTM Avg
9.71x
3Y Avg
14.43x
5Y Avg
26.15x
Market Cap
$868.65M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$849.40M
EV/FCF Ratio
N/A
TTM Avg
241.82x
3Y Avg
97.19x
5Y Avg
51.67x
Market Cap
$846.51M
EV/FCF Ratio
N/A
TTM Avg
197.16x
3Y Avg
197.16x
5Y Avg
197.16x
Market Cap
$877.52M
EV/FCF Ratio
N/A
TTM Avg
14.36x
3Y Avg
10.42x
5Y Avg
10.42x
Market Cap
$836.17M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SI-BONE, Inc. (SIBN) | $861.26M | N/A | N/A | N/A | N/A |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $862.57M | 10.60x | 9.71x | 14.43x | 26.15x |
| SL Science Holding Ltd (SLBT)vs › | $860.77M | N/A | N/A | N/A | N/A |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $868.65M | N/A | N/A | N/A | N/A |
| QuidelOrtho Corporation (QDEL)vs › | $849.40M | N/A | 241.82x | 97.19x | 51.67x |
| Pacific Biosciences of California, Inc. (PACB)vs › | $846.51M | N/A | 197.16x | 197.16x | 197.16x |
| Arbutus Biopharma Corp (ABUS)vs › | $877.52M | N/A | 14.36x | 10.42x | 10.42x |
| SpyGlass Pharma, Inc. Common Stock (SGP)vs › | $836.17M | N/A | N/A | N/A | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $839.96M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $836.35M | N/A | 10.33x | 10.33x | 10.33x |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
